4.7 Review

Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs

期刊

LIFE SCIENCES
卷 274, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2021.119301

关键词

Mycobacterium tuberculosis; Antimycobacterial drugs; Evolution; MDR; Intrinsic resistance

资金

  1. Department of Biotechnology (DBT) for Ramalingaswami fellowship
  2. Indian Council of Medical Research (ICMR) for extra mural grant [5/8/5/27/2019/ECD-1]

向作者/读者索取更多资源

Tuberculosis is one of the deadliest infectious diseases with serious global threat, as the high drug resistance of Mycobacterium tuberculosis leads to increasing number of cases each year. Available antimycobacterial drugs are classified into first line, second line, and third line antibiotics, but years of non-judicious and uncontrolled use have created the significant problem of multidrug-resistant tuberculosis (MDR). Research focuses on new drug candidates, repurposed drugs, and drug combinations for more effective treatment of MDR tuberculosis or reducing chemotherapy time for drug sensitive TB.
Tuberculosis is one of the deadliest infectious diseases existing in the world since ancient times and still possesses serious threat across the globe. Each year the number of cases increases due to high drug resistance shown by Mycobacterium tuberculosis (Mtb). Available antimycobacterial drugs have been classified as First line, Second line and Third line antibiotics depending on the time of their discoveries and their effectiveness in the treatment. These antibiotics have a broad range of targets ranging from cell wall to metabolic processes and their non-judicious and uncontrolled usage in the treatment for years has created a significant problem called multidrug resistant (MDR) tuberculosis. In this review, we have summarized the mechanism of action of all the classified antibiotics currently in use along with the resistance mechanisms acquired by Mtb. We have focused on the new drug candidates/repurposed drugs, and drug in combinations, which are in clinical trials for either treating the MDR tuberculosis more effectively or involved in reducing the time required for the chemotherapy of drug sensitive TB. This information is not discussed very adequately on a single platform. Additionally, we have discussed the recent technologies that are being used to discover novel resistance mechanisms acquired by Mtb and for exploring novel drugs. The story of intrinsic resistance mechanisms and evolution in Mtb is far from complete. Therefore, we have also discussed intrinsic resistance mechanisms of Mtb and their evolution with time, emphasizing the hope for the development of novel antimycobacterial drugs for effective therapy of tuberculosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据